Claims
- 1. Compounds of the formula I ##STR6## in which R.sup.1, R.sup.2 in each case independently of one another are H, A, or Hal, where one of the radicals R.sup.1 or R.sup.2 is always .noteq.H;
- R.sup.1 and R.sup.2 together are also alkylene having 3-5 C atoms;
- R.sup.3, R.sup.4 in each case independently of one another are H, OA, or Hal;
- R.sup.3 and R.sup.4 together are also --O--CH.sub.2 --O-- or --O--CH.sub.2 --CH.sub.2 --O--;
- A is an alkyl having 1 to 6 C atoms;
- X is 1-imidazolyl, 2-methyl-imidazolyl, pyrazolyl, 1,2,4-triazolyl-1-yl or 3-pyridyl;
- Hal is F, Cl, Br, or I and
- n is 1;
- and the physiologically acceptable salts thereof.
- 2. Compounds of the formula I according to claim 1 wherein compounds of the formula I are:
- (a) 2-(1-imidazolyl)-6-methyl-4-(3,4-methylenedioxy-benzylamino)thieno[2,3-d]pyrimidine;
- (b) 2-(1-imidazolyl)-5,6-dimethyl-4-(3,4-methylene-dioxybenzylamino)thieno[2,3-d]pyrimidine;
- (c) 2-(1-imidazolyl)-4-(3,4-methylenedioxybenzyl-amino)-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]-pyrimidine;
- (d) 2-(1-imidazolyl)-5-chloro-4-(3,4-methylenedioxy-benzylamino)thieno[2,3-d]pyrimidine;
- (e) 2-(1-imidazolyl)-6-chloro-4-(3,4-methylenedioxy-benzylamino)thieno[2,3-d]pyrimidine;
- (f) 2-(1,2,4-triazol-1-yl)-4-(3,4-methylenedioxy-benzylamino)-5,6,7,8-tetrahydro[1]benzothieno-[2,3-d]pyrimidine;
- (g) 2-(pyrazol-1-yl)-4-(3,4-methylenedioxybenzyl-amino)-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidine; or
- (h) 2-(Pyridin-3-yl)-4-(3,4-methylenedioxybenzyl-amino)-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidine.
- 3. A process for the preparation of compounds of the formula I according to claim 1 and salts thereof in which X is bonded via N, comprising reacting:
- a) compound of the formula II ##STR7## in which R.sup.1, R.sup.2, R.sup.3, R.sup.4 and n have the abovementioned meanings and L, is Cl, Br, OH, SCH.sub.3 or a reactive esterified OH group with an unsaturated 5-7-membered heterocycle which has at least one NH group and which is unsubstituted or mono-, di- or tri-substituted by A, Hal or CF.sub.3 and in which additionally further CH.sub.2 groups can be replaced by NH, NA, S or O, or
- b) reacting a compound of the formula III ##STR8## in which R.sup.1, R.sup.2 and X has the abovementioned meanings, and L is Cl, Br, OH, SCH.sub.3 or a reactive esterified OH group with a compound of the formula IV ##STR9## in which R.sup.3, R.sup.4 and n have the abovementioned meanings, or
- c) converting a compound of the formula I wherein a radical R.sup.1, R.sup.2, R.sup.3 and/or R.sup.4 into a different radical R.sup.1, R.sup.2, R.sup.3 and/or R.sup.4 by reducing a nitro group, by converting a primary or a secondary amino group into an alkylated amine by reductive amination or by acylating such an amino group, and/or converting a basic compound of the formula I into a salt thereof by treatment with an acid.
- 4. A process for the preparation of pharmaceutical products, comprising bringing a compound of the formula I according to claim 1 and/or a physiologically acceptable salt thereof into a suitable pharmaceutical form together with at least one solid, liquid or semi-liquid excipient or auxiliary.
- 5. A pharmaceutical preparation, comprising at least one compound of the formula I according to claim 1 and/or a physiologically acceptable salt thereof.
- 6. Compounds of the formula I according to claim 1 and the physiologically acceptable salts thereof for combating diseases of the cardiovascular system and for the therapy of impaired potency.
- 7. Pharmaceuticals of the formula I according to claim 1 and the physiologically acceptable salts thereof as phosphodiesterase V inhibitors.
- 8. The compounds of the formula I according to claim 1 wherein A is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, neopentyl, or isopentyl.
- 9. The compounds of the formula I according to claim 1 wherein the compound is 2-(imidazol-1-yl)-5,6,7,8-tetrahydro-4-(3,4-methylene-dioxybenzylamino)[1]benzothieno[2,3-d]pyrimidine.
- 10. The compounds of the formula I according to claim 1 wherein one of R.sup.1 or R.sup.2 is methyl, ethyl, propyl, or butyl and one of R or R.sup.2 is H.
- 11. The compounds of the formula I according to claim 1 wherein R.sup.1 or R.sup.2 together are propylene, butylene, or pentylene.
- 12. The compounds of the formula I according to claim 1 wherein R.sup.3 or R.sup.4 is methoxy, ethoxy, or propoxy.
- 13. The compounds of the formula I according to claim 1 wherein X is imidazolyl or pyridinyl.
- 14. The compounds of the formula I according to claim 13 wherein R.sup.1 or R.sup.2 are a C.sub.3-5 alkylene group.
- 15. The process of claim 3 where the reaction of the compound of formula II further comprises an acid-binding agent.
- 16. The process of claim 3 where the reaction of the compound of formula II further comprises an inert solvent.
- 17. The process according to claim 3 wherein the acid of the salt conversion treatment is an inorganic acid, a hydrohalic acid, a phosphorus acid, or an organic acid.
- 18. A method of treating a cardiovascular disease, an impaired potency, or a disease characterized by raised c GMP comprising administrating to a host a compound of claim 1.
- 19. A method of treating a cardiac insufficiency comprising administrating to a host a compound of claim 1.
Priority Claims (1)
Number |
Date |
Country |
Kind |
196 32 423 |
Aug 1996 |
DEX |
|
Parent Case Info
This application is a 371 of PCT/EP97/04139, filed Jul. 30, 1997.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
102e Date |
371c Date |
PCT/EP97/04139 |
7/30/1997 |
|
|
2/9/1999 |
2/9/1999 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO89/06722 |
2/19/1998 |
|
|
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
4146716 |
Cox et al. |
Mar 1979 |
|
4196207 |
Webber |
Apr 1980 |
|
Foreign Referenced Citations (2)
Number |
Date |
Country |
579496 |
Jan 1994 |
EPX |
728759 |
Aug 1996 |
EPX |